ANVS vs. INCR, CLRB, ADAG, IMUX, SCTL, PDSB, EBS, IOBT, RNAC, and COYA
Should you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include InterCure (INCR), Cellectar Biosciences (CLRB), Adagene (ADAG), Immunic (IMUX), Societal CDMO (SCTL), PDS Biotechnology (PDSB), Emergent BioSolutions (EBS), IO Biotech (IOBT), Cartesian Therapeutics (RNAC), and Coya Therapeutics (COYA). These companies are all part of the "pharmaceutical preparations" industry.
Annovis Bio (NYSE:ANVS) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, community ranking, media sentiment and institutional ownership.
InterCure's return on equity of 0.00% beat Annovis Bio's return on equity.
In the previous week, Annovis Bio had 2 more articles in the media than InterCure. MarketBeat recorded 2 mentions for Annovis Bio and 0 mentions for InterCure. Annovis Bio's average media sentiment score of 0.20 beat InterCure's score of 0.00 indicating that Annovis Bio is being referred to more favorably in the media.
InterCure has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.
Annovis Bio received 13 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 94.12% of users gave Annovis Bio an outperform vote.
Annovis Bio presently has a consensus price target of $27.75, indicating a potential upside of 129.53%. Given Annovis Bio's higher possible upside, analysts clearly believe Annovis Bio is more favorable than InterCure.
Annovis Bio has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500.
15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 38.3% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
InterCure beats Annovis Bio on 8 of the 15 factors compared between the two stocks.
Get Annovis Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Annovis Bio Competitors List
Related Companies and Tools
